Home RegulatoryEurope Medicine Agency (EMA) EMA establishes a Cancer Medicines Forum to optimize Cancer Treatments in Clinical practice

EMA establishes a Cancer Medicines Forum to optimize Cancer Treatments in Clinical practice

by admin
0 comment
EMA , Application , Conditional Marketing , Paxlovid (PF-07321332 and ritonavir) , treating patients , COVID-19

Summary

EMA has launched the Cancer Medicines Forum (CMF) in collaboration with the European Organization for Research and Treatment of Cancer (EORTC). The forum, which brings together representatives from academic organizations and the European medicines regulatory network, aims to advance research into optimizing cancer treatments and will help promote high standards of cancer care in the European Union (EU).

EMA , Application , Conditional Marketing , Paxlovid (PF-07321332 and ritonavir) , treating patients , COVID-19

The European Medicines Agency (EMA)

Since its establishment in 1995, EMA has reviewed and recommended for approval over 170 cancer medicines that have gone on to play an important role in the treatment and management of various types of cancers. The field of oncology has seen the emergence of major innovations in recent years, including the arrival of personalised medicines, immunotherapies, and advanced therapy medicinal products. Such innovations have helped cancer patients across Europe by offering them new tools in their fight against the disease. However, at the time new medicines enter the market, there is an opportunity to improve many aspects with respect to their optimal use and integration into the existing array of treatments. Addressing these opportunities for treatment optimisation may require the conduct of studies to collect robust data to further guide clinical practice.

The Cancer Medicines Forum has met today for the first time to discuss challenges around the research into optimisation of treatments, such as dose-optimisation and similar approaches tailored to the characteristics of the patient and the disease. Meetings will be organised quarterly, including representatives of key academic organisations from EMA’s Healthcare Professionals Working Party. The results of these discussions will support the prioritisation of actions to fight cancer included in the Regulatory Science Strategy to 2025 and the Academia Collaboration Matrix Action Plan. Following a one-year pilot phase, the composition and working procedures of the forum will be re-evaluated.

About EMA

The European Medicines Agency is an agency of the European Union in charge of the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency.

The European Medicines Agency (EMA) protects and promotes human and animal health by evaluating and monitoring medicines within the European Union (EU) and the European Economic Area (EEA).

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

ChemRobotics Times

Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

Laest News

ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

Designed and Developed by Ample eBusiness